Through the eyes of women: the partners' perspective on tadalafil.

Published on Sep 1, 2006in Urology1.924
· DOI :10.1016/J.UROLOGY.2006.03.054
Stanley E. Althof59
Estimated H-index: 59
(Case Western Reserve University),
J. Francois Eid2
Estimated H-index: 2
(Cornell University)
+ 5 AuthorsSanjeev Ahuja11
Estimated H-index: 11
(Eli Lilly and Company)
Objectives. To evaluate patient and female partner responses on the efficacy of, and overall satisfaction with, tadalafil to treat erectile dysfunction using sexual encounter profile (SEP) diaries. Methods. Data were pooled from four double-blind, placebo-controlled, 12-week trials that included 746 couples. Patients were randomized to placebo or tadalafil 10 or 20 mg. Efficacy was evaluated by the mean per-patient/per-partner percentage of “yes” responses to patient SEP questions 1, 2, and 5 and partner SEP questions 1 to 3 (erection achievement, penetration, and overall satisfaction with the sexual experience, respectively) for tadalafil versus placebo. For each SEP question, the number of postbaseline intercourse attempts when each couple agreed on the outcome was tabulated and divided by the total number of postbaseline attempts to calculate the mean percentage of agreement by couple. The overall satisfaction with successful postbaseline intercourse attempts was determined. Results. Tadalafil significantly improved the responses for the patient and partner-evaluated SEP questions (P 0.001, both doses versus placebo). Partners tended to report greater overall satisfaction than patients at baseline and postbaseline. The mean percentage of agreement by couple was approximately 98% for erection achievement and penetration and 85% for overall satisfaction. For successful intercourse attempts, patients and partners treated with tadalafil reported more overall satisfaction than those treated with placebo (P 0.05, tadalafil versus placebo comparisons). Conclusions. Partners reported significantly improved overall sexual satisfaction and corroborated the man’s report of improved erections and penetration ability with tadalafil 10 mg or 20 mg. Men reported improved erection achievement, penetration, and overall satisfaction with the sexual experience after taking tadalafil. UROLOGY 68: 631–635, 2006. © 2006 Elsevier Inc.
📖 Papers frequently viewed together
264 Citations
131 Citations
151 Citations
#1Culley C. Carson (UNC: University of North Carolina at Chapel Hill)H-Index: 64
#2Jacob Rajfer (UCLA Medical Center)H-Index: 72
Last. W.H. Cordell (Eli Lilly and Company)H-Index: 1
view all 8 authors...
OBJECTIVE To provide an update on the efficacy and safety of tadalafil, a phosphodiesterase-5 inhibitor, in the treatment of erectile dysfunction (ED). PATIENTS AND METHODS In all, 2102 men (mean age 56 years) with mild-to-severe ED of various causes were randomized to placebo or tadalafil, taken as needed with no food restrictions, at fixed ‘on-demand’ doses of 10 or 20 mg in 11 randomized, double-blind, placebo-controlled trials lasting 12 weeks. The three co-primary outcomes were changes from...
168 CitationsSource
#1Francesco MontorsiH-Index: 138
#2Stanley E. Althof (Case Western Reserve University)H-Index: 59
Abstract Objectives To evaluate in a pooled analysis of multiple studies the perceptions of effectiveness and overall treatment satisfaction in the partners of patients who received sildenafil citrate for treatment of erectile dysfunction. Partner satisfaction with treatment of erectile dysfunction can have a substantial impact on the continuation of therapy. Methods Each partner rated the man's erectile function and her own intercourse satisfaction by responding to three appropriately modified ...
61 CitationsSource
The new modes of pharmacologic therapy give health care practitioners an unprecedented opportunity to treat patients with erectile dysfunction (ED), an undiagnosed and underreported condition. Yet even with a portfolio ofeffective treatment modalities, such as phosphodiesterase type 5 (PDE5) inhibitors, nonpharmacologic interventions should be considered as means to support and augment the effects of these agents. Of equal value-and necessity-is the involvement of the man's partner in both the a...
20 Citations
ABSTRACTPurpose: Erectile dysfunction affects more than 20 million men in the United States. Currently, there are at least 10 novel erectogenic agents in development. It is incumbent on clinicians and especially urologists to be facile in interpreting data from drug trials investigating such medications.Materials and Methods: A comprehensive review of the literature addressing novel Food and Drug Administration approved erectogenic drugs was conducted using MEDLINE to highlight the key points in...
49 CitationsSource
#1Gerald B. Brock (Taipei Veterans General Hospital)H-Index: 1
#2Chris McMahon (Taipei Veterans General Hospital)H-Index: 59
Last. Steve Whitaker (Taipei Veterans General Hospital)H-Index: 1
view all 8 authors...
ABSTRACTPurpose: We conducted integrated analyses of the efficacy and safety of tadalafil, a potent, selective phosphodiesterase 5 inhibitor, for the treatment of erectile dysfunction.Materials and Methods: A total of 1,112 men with a mean age of 59 years (range 22 to 82) and mild to severe erectile dysfunction of various etiologies were randomized to placebo or tadalafil, taken as needed without food or alcohol restrictions, at fixed daily doses of 2.5 mg., 5 mg., 10 mg., or 20 mg. in 5 randomi...
464 CitationsSource
#1Alan Riley (UCLan: University of Central Lancashire)H-Index: 12
Advances in pharmacological, mechanical, and surgical treatment for erectile dysfunction (ED) now allow erectile function to be re-established in most men who experience this problem. However, re-establishing erectile function and re-establishing a satisfying sexual interaction with a partner are totally different objectives, and when the latter is not met, the man may re-present with treatment failure or withdraw from treatment altogether. All nontalking therapies focus on the penis as the dysf...
76 CitationsSource
#1Harin Padma-Nathan (SC: University of Southern California)H-Index: 36
#2JG McMurrayH-Index: 1
Last. Raymond C. Rosen (RU: Rutgers University)H-Index: 127
view all 7 authors...
IC351 (Cialis™) is a selective inhibitor of PDE5. The efficacy and safety of on-demand dosing of IC351 in men with erectile dysfunction was assessed in a multicenter, double-blind, placebo-controlled study. One hundred seventy-nine men (mean age: 56 y) were randomized to receive placebo or IC351 at doses of 2, 5, 10 or 25 mg, taken on demand over a 3-week period. The primary endpoints were change from baseline in responses to Questions 3 (Q3) and 4 (Q4) of the International Index of Erectile Fun...
188 CitationsSource
#1G. WagnerH-Index: 1
#2Kerstin S. Fugl-Meyer (Uppsala University)H-Index: 26
Last. Axel R. Fugl-Meyer (Uppsala University)H-Index: 41
view all 3 authors...
Quality of life (QoL) has become one of the important parameters in the evaluation of treatment and assessment of medical conditions, and it may be an important tool in determining the urgency of the need for therapeutic intervention for erectile dysfunction (ED). It is important to evaluate QoL of the couple, because men and women alike will suffer because of male erectile disability. Future drug trials, as well as studies of sexological intervention programs, should involve both partners.
88 CitationsSource
#1Susan D. Mathias (RU: Rutgers University)H-Index: 1
#1Susan D. Mathias (RU: Rutgers University)H-Index: 29
Last. Raymond C. Rosen (RU: Rutgers University)H-Index: 127
view all 6 authors...
Purpose:: Patient self-administered questionnaires have recently been developed to assess sexual function in men with erectile dysfunction. However, it may also be important to assess satisfaction with and any improvements in sexual function from the perspective of the female partner. We report the results of a brief 3-item questionnaire developed for the female partner and its association with an 11-item questionnaire developed for men with erectile dysfunction.Materials and Methods:: Men and t...
28 CitationsSource
: Quality of Life (QOL) is an important outcome dimension in clinical trials of sexual dysfunction. This brief paper reviews the rationale for inclusion of QOL measures in clinical trials and considers the use of broad-based or generic measures of QOL, compared to disease-specific measures. Two disease-specific measures of QOL associated with erectile dysfunction are presented in detail. Each of these measures has certain advantages, although neither has been sufficiently validated to warrant la...
42 Citations
Cited By36
#1Emmanuele A. Jannini (University of Rome Tor Vergata)H-Index: 70
#1Emmanuele A. Jannini (University of Rome Tor Vergata)H-Index: 17
Last. Rossella E. Nappi (UNIPV: University of Pavia)H-Index: 62
view all 2 authors...
Abstract Background At midlife and beyond, both men and women face organic changes that can affect sexual functioning. For women, ovarian exhaustion causes estrogen deficiency, leading to genitourinary syndrome of menopause, which may include vaginal dryness, irritation/itching, inadequate lubrication, and dyspareunia. Hypoactive sexual desire disorder also can result from biopsychosocial factors. For men, erectile dysfunction prevalence increases with age, and some men develop testosterone defi...
32 CitationsSource
#1Thomas Parisi (Western University of Health Sciences)H-Index: 2
#2Robert N. Pechnick (UWO: University of Western Ontario)
Last. Waguih William IsHak (UCLA: University of California, Los Angeles)H-Index: 32
view all 3 authors...
Awareness of the biological and the psychological considerations in sexual performance is crucial in the exploration of treatments that promote sexual enhancement. Biological factors include, but are not limited to, genetic makeup, physical health, and nutrition. Psychosocial factors involve upbringing, belief systems, self-efficacy, relationships, personality, and experiences. Improving and enhancing sexual function pharmacologically include approved and off-label medications and are based part...
#1Konstantinos Hatzimouratidis (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 26
#2Andrea SaloniaH-Index: 82
Last. Mohit Khera (BCM: Baylor College of Medicine)H-Index: 31
view all 9 authors...
Abstract Introduction Treatment of erectile dysfunction is based on pharmacotherapy for most patients. Aim To review the current data on pharmacotherapy for erectile dysfunction based on efficacy, psychosocial outcomes, and safety outcomes. Methods A review of the literature was undertaken by the committee members. All related articles were critically analyzed and discussed. Main Outcome Measures Levels of evidence (LEs) and grades of recommendations (GRs) are provided based on a thorough analys...
98 CitationsSource
#1Patrick R. Burns (Eli Lilly and Company)H-Index: 9
#2Raymond C. RosenH-Index: 127
Last. Michael A. Perelman (Cornell University)H-Index: 27
view all 5 authors...
Abstract Introduction Treatment satisfaction of men receiving phosphodiesterase 5 inhibitors (PDE5) for erectile dysfunction (ED) and their partners is essential to successful long‐term therapy. Aim This study aims to assess treatment satisfaction, in men with a partial response to on‐demand (PRN) PDE5 and their female partners, following tadalafil 5 mg once daily or placebo. Methods The study was randomized, double‐blind, parallel, and placebo‐controlled in men primarily with mild to moderate E...
9 CitationsSource
Last. Sirel Gurbuz (Eli Lilly and Company)H-Index: 5
view all 6 authors...
AbstractBackground:Phosphodiesterase type 5 (PDE5) inhibitors have discontinuation rates as high as 60% in men with erectile dysfunction. Treatment satisfaction has been significantly associated with treatment continuation. Understanding key characteristics in terms of treatment preference, relationship, and lifestyle issues could provide direction on how to improve compliance with PDE5 inhibitor treatment globally.Objective:The objective was to identify subgroups of interest in the pooled datab...
3 CitationsSource
#1Ozgoli Giti (TMU: Tarbiat Modares University)
#2Ziaei Saeideh (TMU: Tarbiat Modares University)H-Index: 3
Last. Azar Mahyar (Shahid Beheshti University of Medical Sciences and Health Services)
view all 4 authors...
Resume La dysfonction erectile (DE) touche en moyenne un homme sur cinq dans le monde. Elle est habituellement 4,5 fois plus frequente chez le diabetique, chez lequel elle survient en moyenne dix a 15 ans plus tot que pour les autres hommes. La DE revet chez le diabetique une valeur hautement semeiologique car elle marque, par son installation, une etape significative de l’evolution du diabete et de son retentissement visceral. Elle apparait aujourd’hui comme l’indicateur le plus fiable des comp...
2 CitationsSource
Summary Sexuality is frequently affected in diabetic patients. While one man in five suffers from erectile dysfunction (ED) in the general population, ED is 4.5 times more frequently observed in diabetic patients and starts 10 to 15 years earlier than in non-diabetics. ED in diabetic patients has significant semeiological value: it shows a significant change in the diabetes and its impact on the organs. It appears today to be the most reliable indicator of micro-angiopathic complications of diab...
4 CitationsSource
#1H. Claes (Katholieke Universiteit Leuven)H-Index: 10
#2Robert AndrianneH-Index: 7
Last. Kathleen Commers (Pfizer)H-Index: 2
view all 6 authors...
INTRODUCTION: The HelpED study assessed men with erectile dysfunction (ED) treated with a phosphodiesterase type 5 (PDE5) inhibitor and their female partner in a community setting. AIM: To examine agreement in Erection Hardness Score (EHS) in patients and partners; to assess impact of EHS changes on other sexual health outcomes and behaviors. METHODS: At baseline and follow-up 2 to 4 months later, men in a stable heterosexual relationship who had newly diagnosed or untreated ED (≥6 months) compl...
11 CitationsSource
#1Giovanni Corona (UniFI: University of Florence)H-Index: 84
#2Valdo Ricca (UniFI: University of Florence)H-Index: 58
Last. Mario Maggi (UniFI: University of Florence)H-Index: 160
view all 10 authors...
ABSTRACT Introduction We previously developed and validated a structured interview (SIEDY) dealing with the organic (Scale 1), relational (Scale 2), and psychological (Scale 3) components of erectile dysfunction (ED). Aim To identify a pathological threshold for SIEDY Scale 3 and to analyze Scale 3 score with biological and psychological correlates in subjects with sexual dysfunction. Method A pathological threshold of SIEDY Scale 3 score in predicting subjects with a medical history of psychopa...
59 CitationsSource